Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. It operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. It also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, the company provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. It provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Elevance Health Inc.

In a report released yesterday, Lance Wilkes from Bernstein assigned a Buy rating to Elevance Health, with a price target of $384.00. The company’s...

Elevance Health (ELV) Gets a Buy from Bernstein

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Enliven Therapeutics, with a price target of $45.00. According ...

JonesTrading Keeps Their Buy Rating on Enliven Therapeutics (ELVN)

Medicare payments are a big source of revenue for health insurers. 


HUM, UNH, CVS: Healthcare Stocks Soar on 2.48% Medicare Rate Increase

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pha...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (DMAC), Elevance Health (ELV) and Oric Pharmaceuticals (ORIC)

Macquarie analyst maintained a Buy rating on Elevra Lithium today and set a price target of A$10.30. Currently, the analyst consensus on Elevra Lit...

Macquarie Keeps Their Buy Rating on Elevra Lithium (SYAXF)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Enliven Therapeutics today and set a price target of $53.00. According to TipRanks, ...

LifeSci Capital Keeps Their Buy Rating on Enliven Therapeutics (ELVN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioAge Labs, Inc. (BIOA) and Enliven Therapeutics (ELVN). BioAge ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioAge Labs, Inc. (BIOA) and Enliven Therapeutics (ELVN)

An update from Elevra Lithium ( ($AU:ELV) ) is now available. Elevra Lithium has completed a small shareholding sale facility aimed at consolidatin...

Elevra Lithium Trims Small Shareholdings to Cut Admin Costs

Elevra Lithium ( ($AU:ELV) ) has issued an update. Elevra Lithium has filed a NI 43-101 compliant technical report supporting its previously releas...

Elevra Lithium lodges NI 43-101 report to advance NAL expansion plans

Elevance Health ( ($ELV) ) has provided an announcement. Officers of Elevance Health said they will meet investors and analysts over the coming wee...

Elevance Health Reaffirms 2026 Earnings Guidance Amid CMS Risks

Electrovaya ( ($TSE:ELVA) ) just unveiled an update. Electrovaya has secured UL 2580 safety certification for six models of its next-generation hig...

Current Quarter	$10.61	Next Quarter	$6.44
Current Year	$25.93	Next Year	$29.25
QoQ Growth	-39.3%	YoY Growth	+12.8%
3Y EPS CAGR	N/A	Target Price	$376.05
Consensus	Buy	Upside	+17.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ELV	$319.06	+2.32%	656.23K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ELV	$319.06	+2.3%	656.23K
3
4
5
6

ELV

ELV

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Elevance Health Inc. Data in Excel

Get Elevance Health Inc. Data in Excel